LABELS · 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
Methotrexate
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2025-06-10
- Captured
- 2026-09-09T23:37:54.830918+00:00
- Current indication reconciliation
- Not reconciled
Boxed warning in this label
- WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS • Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Methotrexate Injection is contraindicated in pregnancy. Advise females and males of reproductive potential to use effective contraception [see Contraindications (4) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1 , 8.3) ] . • Methotrexate Injection is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis [see Contraindications (4) and Warnings and Precautions (5.2) ]. • Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free Methotrexate Injection for treatment of neonates or low birth weight infants and for intrathecal use. Do not use benzyl alcohol-containing formulations for high-dose regimens unless immediate treatment is required and preservative-free formulations are not available [see Dosage and Administration (2.1) and Warnings and Precautions (5.3) ]. • Other serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, kidneys, liver, nervous system, gastrointestinal tract, lungs, and skin. Withhold or discontinue Methotrexate Injection as appropriate [see Warnings and Precautions (5.4 , 5.5 , 5.6 , 5.7 , 5.8 , 5.9 , 5.10 , 5.11) ]. WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS See full prescribing information for complete boxed warning . • Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. Use in non-neoplastic diseases is contraindicated during pregnancy. Advise females and males of reproductive potential to use effective contraception during and after treatment with Methotrexate Injection. ( 4 , 5.1 , 8.1 , 8.3 ) • Methotrexate Injection is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis. ( 4 , 5.2 ) • Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free Methotrexate Injection for treatment of neonates or low birth weight infants, and for intrathecal use. Do not use benzyl alcohol-containing formulations for high-dose regimens unless immediate treatment is required and preservative-free formulations are not available. ( 2.1 , 5.3 ) • Other serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, kidneys, liver, nervous system, gastrointestinal tract, lungs, and skin. Withhold or discontinue Methotrexate Injection as appropriate. ( 5.4 , 5.5 , 5.6 , 5.7 , 5.8 , 5.9 , 5.10 , 5.11 )
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE Methotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen. ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. 1.2 Meningeal Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. 1.3 Non-Hodgkin Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma. 1.4 Osteosarcoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. 1.5 Breast Cancer Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. 1.6 Squamous Cell Carcinoma of the Head and Neck Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single agent. 1.7 Gestational Trophoblastic Neoplasia Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen. 1.8 Rheumatoid Arthritis Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA). 1.9 Polyarticular Juvenile Idiopathic Arthritis Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA). 1.10 Psoriasis Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.
Full extracted label fields
- application numbers
- NDA011719
- boxed warning exact
- WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS • Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Methotrexate Injection is contraindicated in pregnancy. Advise females and males of reproductive potential to use effective contraception [see Contraindications (4) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1 , 8.3) ] . • Methotrexate Injection is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis [see Contraindications (4) and Warnings and Precautions (5.2) ]. • Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free Methotrexate Injection for treatment of neonates or low birth weight infants and for intrathecal use. Do not use benzyl alcohol-containing formulations for high-dose regimens unless immediate treatment is required and preservative-free formulations are not available [see Dosage and Administration (2.1) and Warnings and Precautions (5.3) ]. • Other serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, kidneys, liver, nervous system, gastrointestinal tract, lungs, and skin. Withhold or discontinue Methotrexate Injection as appropriate [see Warnings and Precautions (5.4 , 5.5 , 5.6 , 5.7 , 5.8 , 5.9 , 5.10 , 5.11) ]. WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS See full prescribing information for complete boxed warning . • Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. Use in non-neoplastic diseases is contraindicated during pregnancy. Advise females and males of reproductive potential to use effective contraception during and after treatment with Methotrexate Injection. ( 4 , 5.1 , 8.1 , 8.3 ) • Methotrexate Injection is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis. ( 4 , 5.2 ) • Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free Methotrexate Injection for treatment of neonates or low birth weight infants, and for intrathecal use. Do not use benzyl alcohol-containing formulations for high-dose regimens unless immediate treatment is required and preservative-free formulations are not available. ( 2.1 , 5.3 ) • Other serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, kidneys, liver, nervous system, gastrointestinal tract, lungs, and skin. Withhold or discontinue Methotrexate Injection as appropriate. ( 5.4 , 5.5 , 5.6 , 5.7 , 5.8 , 5.9 , 5.10 , 5.11 )
- brand names
- Methotrexate
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d63ba29-b692-41b4-87e8-351265c8273f
- generic names
- METHOTREXATE
- id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- indications and usage exact
- 1 INDICATIONS AND USAGE Methotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen. ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. 1.2 Meningeal Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. 1.3 Non-Hodgkin Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma. 1.4 Osteosarcoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. 1.5 Breast Cancer Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. 1.6 Squamous Cell Carcinoma of the Head and Neck Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single agent. 1.7 Gestational Trophoblastic Neoplasia Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen. 1.8 Rheumatoid Arthritis Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA). 1.9 Polyarticular Juvenile Idiopathic Arthritis Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA). 1.10 Psoriasis Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- Hospira, Inc.
- matched search terms
- cancer
- carcinoma
- lymphoma
- leukemia
- package ndcs
- 61703-350-37
- 61703-350-38
- 61703-408-41
- product ndcs
- 61703-350
- 61703-408
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- Warnings and Precautions ( 5.11 ) 05/2025
- record type
- complete_spl_indications_section_candidate
- routes
- INTRAMUSCULAR
- INTRAVENOUS
- SUBCUTANEOUS
- INTRATHECAL
- rxcuis
- 1655956
- 1946772
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00500.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 500
- total
- 830
- sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl effective time
- 20250610
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- substance names
- METHOTREXATE SODIUM
- uniis
- 3IG1E710ZN
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
Drugs@FDA application source records
- application number
- NDA011719
- payload
- all indexed label documents
- Appl No
- 011719
- Application Docs Date
- 2004-02-03 00:00:00
- Application Docs ID
- 10774
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11719slr106_methotrexate_lbl.pdf
- Submission No
- 106
- Submission Type
- SUPPL
- Appl No
- 011719
- Application Docs Date
- 2015-11-25 00:00:00
- Application Docs ID
- 10775
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011719s122lbl.pdf
- Submission No
- 122
- Submission Type
- SUPPL
- Appl No
- 011719
- Application Docs Date
- 2011-11-04 00:00:00
- Application Docs ID
- 33054
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011719s117lbl.pdf
- Submission No
- 117
- Submission Type
- SUPPL
- Appl No
- 011719
- Application Docs Date
- 2018-03-16 00:00:00
- Application Docs ID
- 53041
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011719s126lbl.pdf
- Submission No
- 126
- Submission Type
- SUPPL
- Appl No
- 011719
- Application Docs Date
- 2018-05-07 00:00:00
- Application Docs ID
- 54036
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011719s125lbl.pdf
- Submission No
- 125
- Submission Type
- SUPPL
- Appl No
- 011719
- Application Docs Date
- 2021-04-19 00:00:00
- Application Docs ID
- 66921
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/011719Orig1s131lbl.pdf
- Submission No
- 131
- Submission Type
- SUPPL
- Appl No
- 011719
- Application Docs Date
- 2022-05-03 00:00:00
- Application Docs ID
- 70913
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/011719Orig1s135lbl.pdf
- Submission No
- 135
- Submission Type
- SUPPL
- Appl No
- 011719
- Application Docs Date
- 2023-11-17 00:00:00
- Application Docs ID
- 76607
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/011719s138lbl.pdf
- Submission No
- 138
- Submission Type
- SUPPL
- Appl No
- 011719
- Application Docs Date
- 2024-07-16 00:00:00
- Application Docs ID
- 79104
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/011719Orig1s136lbl.pdf
- Submission No
- 136
- Submission Type
- SUPPL
- Appl No
- 011719
- Application Docs Date
- 2025-05-30 00:00:00
- Application Docs ID
- 82358
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/011719s142lbl.pdf
- Submission No
- 142
- Submission Type
- SUPPL
- all submission records
- Appl No
- 011719
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 70
- Submission Status
- AP
- Submission Status Date
- 1987-03-19 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 63
- Submission Status
- AP
- Submission Status Date
- 1983-04-08 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- Submission Class Code ID
- 3
- Submission No
- 62
- Submission Status
- AP
- Submission Status Date
- 1982-08-24 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 59
- Submission Status
- AP
- Submission Status Date
- 1983-04-08 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 58
- Submission Status
- AP
- Submission Status Date
- 1982-03-31 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- Submission Class Code ID
- 3
- Submission No
- 57
- Submission Status
- AP
- Submission Status Date
- 1982-03-31 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 56
- Submission Status
- AP
- Submission Status Date
- 1981-12-07 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 54
- Submission Status
- AP
- Submission Status Date
- 1981-05-11 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 53
- Submission Status
- AP
- Submission Status Date
- 1980-12-03 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 52
- Submission Status
- AP
- Submission Status Date
- 1980-02-29 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 51
- Submission Status
- AP
- Submission Status Date
- 1979-10-15 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 011719
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 50
- Submission Status
- AP
- Submission Status Date
- 1980-06-11 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- application number
- NDA011719
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011719
- has approved submission record
- true
- latest approved submission date
- 2025-05-28
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 011719
- Application Docs Date
- 2025-05-30 00:00:00
- Application Docs ID
- 82358
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/011719s142lbl.pdf
- Submission No
- 142
- Submission Type
- SUPPL
- official application record
- Appl No
- 011719
- Appl Public Notes
- Appl Type
- NDA
- Sponsor Name
- HOSPIRA
- openfda application present
- true
- products
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE SODIUM
- Form
- INJECTABLE;INJECTION
- Product No
- 001
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 20MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- marketing status
- Discontinued
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE SODIUM
- Form
- INJECTABLE;INJECTION
- Product No
- 003
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 50MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- marketing status
- Discontinued
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE SODIUM
- Form
- INJECTABLE;INJECTION
- Product No
- 004
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 2.5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- marketing status
- Discontinued
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE SODIUM
- Form
- INJECTABLE;INJECTION
- Product No
- 005
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 25MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- marketing status
- Discontinued
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE SODIUM
- Form
- INJECTABLE;INJECTION
- Product No
- 006
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- marketing status
- Discontinued
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE LPF
- Form
- INJECTABLE;INJECTION
- Product No
- 007
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 25MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- marketing status
- Discontinued
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE SODIUM PRESERVATIVE FREE
- Form
- INJECTABLE;INJECTION
- Product No
- 009
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- marketing status
- Discontinued
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE SODIUM
- Form
- INJECTABLE;INJECTION
- Product No
- 010
- Reference Drug
- 1
- Reference Standard
- 1
- Strength
- EQ 50MG BASE/2ML (EQ 25MG BASE/ML)
- marketing status
- Prescription
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE PRESERVATIVE FREE
- Form
- INJECTABLE;INJECTION
- Product No
- 011
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- marketing status
- Discontinued
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE SODIUM PRESERVATIVE FREE
- Form
- INJECTABLE;INJECTION
- Product No
- 012
- Reference Drug
- 1
- Reference Standard
- 1
- Strength
- EQ 1GM BASE/40ML (EQ 25MG BASE/ML)
- marketing status
- Prescription
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE PRESERVATIVE FREE
- Form
- INJECTABLE;INJECTION
- Product No
- 013
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- marketing status
- Discontinued
- Active Ingredient
- METHOTREXATE SODIUM
- Appl No
- 011719
- Drug Name
- METHOTREXATE PRESERVATIVE FREE
- Form
- INJECTABLE;INJECTION
- Product No
- 014
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 20MG BASE/2ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- marketing status
- Discontinued
Source passages and status connections
Passage 1 · indication intro context
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- incomplete_colon_led_indication_intro
- clinical review status
- pending
- content role
- indication_intro_context
- context span
- end
- 300
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Methotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. ( 1.1 ) o Prophylaxis and tre
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-5dcd38bf6460274b4a1e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-d5d2788323c95259239c
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 95
- end exclusive
- true
- exact text
- is a folate analog metabolic inhibitor indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 47
- qualifier mentions
- context exact
- 1 INDICATIONS AND USAGE Methotrexate Injection is a folate analog metabolic inhibitor indicated for:
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 67
- end exclusive
- true
- exact text
- Methotrexate Injection is a folate analog m
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 24
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 100
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Methotrexate Injection is a folate analog metabolic inhibitor indicated for:
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 2 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 470
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Methotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. ( 1.3 ) o Treatment of adul
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-f7ee3d5c43d08f537918
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-999451aa9253d471e9d0
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 95
- end exclusive
- true
- exact text
- is a folate analog metabolic inhibitor indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 47
- qualifier mentions
- context exact
- • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as
- kind
- age
- polarity
- not_inferred
- span
- end
- 166
- end exclusive
- true
- exact text
- adult
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 161
- context exact
- owing neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination
- kind
- age
- polarity
- not_inferred
- span
- end
- 189
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 171
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 270
- end exclusive
- true
- exact text
- • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 101
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 3 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 563
- end exclusive
- true
- exact text
- olic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. ( 1
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 71
- current approval status
- not_reconciled
- duplicate text group
- dup-eb00b72d12f8149d1d7b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-eab365f2ad7e12aa84da
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 95
- end exclusive
- true
- exact text
- is a folate analog metabolic inhibitor indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 47
- qualifier mentions
- context exact
- ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia.
- kind
- age
- polarity
- not_inferred
- span
- end
- 315
- end exclusive
- true
- exact text
- adult
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 310
- context exact
- ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia.
- kind
- age
- polarity
- not_inferred
- span
- end
- 338
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 320
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 363
- end exclusive
- true
- exact text
- ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 271
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 4 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 642
- end exclusive
- true
- exact text
- lt and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemothe
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 164
- current approval status
- not_reconciled
- duplicate text group
- dup-7165671bb73494ad0641
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-4cbbe3f4b680c08e1b64
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 95
- end exclusive
- true
- exact text
- is a folate analog metabolic inhibitor indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 47
- qualifier mentions
- context exact
- ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma.
- kind
- age
- polarity
- not_inferred
- span
- end
- 392
- end exclusive
- true
- exact text
- adult
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 387
- context exact
- ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma.
- kind
- age
- polarity
- not_inferred
- span
- end
- 415
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 397
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 442
- end exclusive
- true
- exact text
- ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 364
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 5 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 759
- end exclusive
- true
- exact text
- ation chemotherapy regimen. ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen. ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. ( 1.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 243
- current approval status
- not_reconciled
- duplicate text group
- dup-1f9aa7a599ea2872f8fa
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-ca9e64ca78e4f1fcf652
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 95
- end exclusive
- true
- exact text
- is a folate analog metabolic inhibitor indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 47
- qualifier mentions
- context exact
- ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combi
- kind
- age
- polarity
- not_inferred
- span
- end
- 471
- end exclusive
- true
- exact text
- adult
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 466
- context exact
- ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy reg
- kind
- age
- polarity
- not_inferred
- span
- end
- 494
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 476
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 559
- end exclusive
- true
- exact text
- ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 443
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 6 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 855
- end exclusive
- true
- exact text
- ia. ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen. ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chem
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 360
- current approval status
- not_reconciled
- duplicate text group
- dup-ac794a4420f26a15540e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-cf8e0d1e2684c05d9be6
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 95
- end exclusive
- true
- exact text
- is a folate analog metabolic inhibitor indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 47
- qualifier mentions
- context exact
- ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy re
- kind
- age
- polarity
- not_inferred
- span
- end
- 589
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 583
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 655
- end exclusive
- true
- exact text
- ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 560
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 7 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 954
- end exclusive
- true
- exact text
- atment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen. ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 456
- current approval status
- not_reconciled
- duplicate text group
- dup-0dc510dd8c9ab045d0aa
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-f2391e4688bdef2538ee
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 95
- end exclusive
- true
- exact text
- is a folate analog metabolic inhibitor indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 47
- qualifier mentions
- context exact
- ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as a sing
- kind
- age
- polarity
- not_inferred
- span
- end
- 685
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 679
- context exact
- of adults with squamous cell carcinoma of the head and neck as a single agent.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 753
- end exclusive
- true
- exact text
- as a single agent
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 736
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 754
- end exclusive
- true
- exact text
- ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 656
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 8 · unclassified context
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1072
- end exclusive
- true
- exact text
- men. ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen. ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with sev
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 555
- current approval status
- not_reconciled
- duplicate text group
- dup-f76acfb2660716696edc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-3d2e1ae3974699a86452
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combi
- kind
- age
- polarity
- not_inferred
- span
- end
- 784
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 778
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 872
- end exclusive
- true
- exact text
- ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 755
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 9 · unclassified context
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1080
- end exclusive
- true
- exact text
- nt of adults with squamous cell carcinoma of the head and neck as a single agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psor
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 673
- current approval status
- not_reconciled
- duplicate text group
- dup-77f7ae06af89907be1f9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-e279e13c722e48fa0857
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 880
- end exclusive
- true
- exact text
- ( 1.7 )
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 873
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 10 · unclassified context
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1134
- end exclusive
- true
- exact text
- ults with squamous cell carcinoma of the head and neck as a single agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Metho
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 681
- current approval status
- not_reconciled
- duplicate text group
- dup-b6b0a6aee170c923a4e0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-a05dc8d95878a92c1062
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • Treatment of adults with rheumatoid arthritis (RA).
- kind
- age
- polarity
- not_inferred
- span
- end
- 902
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 896
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 934
- end exclusive
- true
- exact text
- • Treatment of adults with rheumatoid arthritis (RA).
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 881
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 11 · unclassified context
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1142
- end exclusive
- true
- exact text
- as a single agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 735
- current approval status
- not_reconciled
- duplicate text group
- dup-692d0adb8ba3ac214d4a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-254b6b26f5330e931406
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 942
- end exclusive
- true
- exact text
- ( 1.8 )
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 935
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · unclassified context
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1233
- end exclusive
- true
- exact text
- ngle agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphob
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 743
- current approval status
- not_reconciled
- duplicate text group
- dup-97c21b8e0cb1b45b01f6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-2999c647598bc3d7c243
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
- kind
- age
- polarity
- not_inferred
- span
- end
- 976
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 958
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 1033
- end exclusive
- true
- exact text
- • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 943
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 13 · unclassified context
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1241
- end exclusive
- true
- exact text
- of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic l
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 834
- current approval status
- not_reconciled
- duplicate text group
- dup-2ccb9af347ac5696e174
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-abf82fc18102ae81d40f
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 1041
- end exclusive
- true
- exact text
- ( 1.9 )
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1034
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 14 · unclassified context
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1286
- end exclusive
- true
- exact text
- bination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemot
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 842
- current approval status
- not_reconciled
- duplicate text group
- dup-7fc3ffec7bac4317e9cb
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-48ec69a567c07682da77
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • Treatment of adults with severe psoriasis.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1063
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1057
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 1086
- end exclusive
- true
- exact text
- • Treatment of adults with severe psoriasis.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1042
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 15 · unclassified context
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1295
- end exclusive
- true
- exact text
- tment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy re
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 887
- current approval status
- not_reconciled
- duplicate text group
- dup-3961f8a5c58a4c5e2c9f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-f2b97e4de3ffc3e91a00
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 1095
- end exclusive
- true
- exact text
- ( 1.10 )
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1087
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 16 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1501
- end exclusive
- true
- exact text
- adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. 1.2 Meningeal Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. 1.3 Non-Hodgkin Lymphoma
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 896
- current approval status
- not_reconciled
- duplicate text group
- dup-34ff16ede24e68c03a22
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-b149bcfe8c2c7f2132c9
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 1164
- end exclusive
- true
- exact text
- is indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1152
- qualifier mentions
- context exact
- ia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (A
- kind
- age
- polarity
- not_inferred
- span
- end
- 1191
- end exclusive
- true
- exact text
- adult
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1186
- context exact
- exate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combin
- kind
- age
- polarity
- not_inferred
- span
- end
- 1214
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1196
- context exact
- 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lympho
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1172
- end exclusive
- true
- exact text
- Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1129
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 1301
- end exclusive
- true
- exact text
- 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1096
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 17 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1676
- end exclusive
- true
- exact text
- ute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. 1.2 Meningeal Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. 1.3 Non-Hodgkin Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma. 1.4 Osteosarcoma Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1102
- current approval status
- not_reconciled
- duplicate text group
- dup-fc5a13c0a9855ae81e7f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-b6b5284bdb1213169f8f
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 1387
- end exclusive
- true
- exact text
- is indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1375
- qualifier mentions
- context exact
- for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1452
- end exclusive
- true
- exact text
- adult
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1447
- context exact
- rophylaxis and treatment of meningeal leukemia in adult and pediatric patients.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1475
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1457
- context exact
- 1.2 Meningeal Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult an
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1395
- end exclusive
- true
- exact text
- Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1352
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 1476
- end exclusive
- true
- exact text
- 1.2 Meningeal Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1302
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 18 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1815
- end exclusive
- true
- exact text
- on chemotherapy regimen. 1.2 Meningeal Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. 1.3 Non-Hodgkin Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma. 1.4 Osteosarcoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. 1.5 Breast Cancer Methotrexate
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1277
- current approval status
- not_reconciled
- duplicate text group
- dup-b28ae7178a35965b3702
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-a20038db7bc76fc981b5
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 1537
- end exclusive
- true
- exact text
- is indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1525
- qualifier mentions
- context exact
- ma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1565
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1559
- context exact
- xate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1588
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1570
- context exact
- 1.3 Non-Hodgkin Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1545
- end exclusive
- true
- exact text
- Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1502
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 1615
- end exclusive
- true
- exact text
- 1.3 Non-Hodgkin Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1477
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 19 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1984
- end exclusive
- true
- exact text
- tment of meningeal leukemia in adult and pediatric patients. 1.3 Non-Hodgkin Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma. 1.4 Osteosarcoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. 1.5 Breast Cancer Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. 1.6 Squamous Cell Carcinoma of the Head and Neck Me
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1416
- current approval status
- not_reconciled
- duplicate text group
- dup-06d97ae43474b6cd666d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-3eea5aed6427ab85e22a
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 1668
- end exclusive
- true
- exact text
- is indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1656
- qualifier mentions
- context exact
- ma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combi
- kind
- age
- polarity
- not_inferred
- span
- end
- 1696
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1690
- context exact
- xate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy reg
- kind
- age
- polarity
- not_inferred
- span
- end
- 1719
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1701
- context exact
- 1.4 Osteosarcoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcom
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1676
- end exclusive
- true
- exact text
- Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1633
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 1784
- end exclusive
- true
- exact text
- 1.4 Osteosarcoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1616
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 20 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2132
- end exclusive
- true
- exact text
- nts with non-Hodgkin lymphoma. 1.4 Osteosarcoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. 1.5 Breast Cancer Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. 1.6 Squamous Cell Carcinoma of the Head and Neck Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single agent. 1.7 Gestational T
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1585
- current approval status
- not_reconciled
- duplicate text group
- dup-3d138a04b13199cb3252
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-481a87bc4ecfd0f9f656
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 1838
- end exclusive
- true
- exact text
- is indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1826
- qualifier mentions
- context exact
- er Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy re
- kind
- age
- polarity
- not_inferred
- span
- end
- 1866
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1860
- context exact
- 1.5 Breast Cancer Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combina
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1846
- end exclusive
- true
- exact text
- Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1803
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 1932
- end exclusive
- true
- exact text
- 1.5 Breast Cancer Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1785
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 21 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2314
- end exclusive
- true
- exact text
- coma as part of a combination chemotherapy regimen. 1.5 Breast Cancer Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. 1.6 Squamous Cell Carcinoma of the Head and Neck Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single agent. 1.7 Gestational Trophoblastic Neoplasia Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen. 1
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1733
- current approval status
- not_reconciled
- duplicate text group
- dup-1ac92636ba016df527d0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-3ce2310142d074fb718e
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 2017
- end exclusive
- true
- exact text
- is indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2005
- qualifier mentions
- context exact
- ck Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a sing
- kind
- age
- polarity
- not_inferred
- span
- end
- 2045
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2039
- context exact
- 1.6 Squamous Cell Carcinoma of the Head and Neck Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the hea
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2025
- end exclusive
- true
- exact text
- Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1982
- context exact
- of adults with squamous cell carcinoma of the head and neck as a single agent.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2113
- end exclusive
- true
- exact text
- as a single agent
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2096
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 2114
- end exclusive
- true
- exact text
- 1.6 Squamous Cell Carcinoma of the Head and Neck Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single agent.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1933
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 22 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2512
- end exclusive
- true
- exact text
- otherapy regimen. 1.6 Squamous Cell Carcinoma of the Head and Neck Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single agent. 1.7 Gestational Trophoblastic Neoplasia Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen. 1.8 Rheumatoid Arthritis Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA). 1.9 Polyarticular Juvenile Idiopathic Arthritis Methotrexate Injection is indi
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 1915
- current approval status
- not_reconciled
- duplicate text group
- dup-c269381c03911ad28958
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-1d198dfbd279c4a55762
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 2190
- end exclusive
- true
- exact text
- is indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2178
- qualifier mentions
- context exact
- ia Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a
- kind
- age
- polarity
- not_inferred
- span
- end
- 2218
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2212
- context exact
- 1.7 Gestational Trophoblastic Neoplasia Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasi
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2198
- end exclusive
- true
- exact text
- Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2155
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 2312
- end exclusive
- true
- exact text
- 1.7 Gestational Trophoblastic Neoplasia Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2115
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 23 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2633
- end exclusive
- true
- exact text
- . 1.7 Gestational Trophoblastic Neoplasia Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen. 1.8 Rheumatoid Arthritis Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA). 1.9 Polyarticular Juvenile Idiopathic Arthritis Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA). 1.10 Psoriasis Met
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2113
- current approval status
- not_reconciled
- duplicate text group
- dup-5a1e410367377eef80b0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-a5c247f04a7077820c61
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 2373
- end exclusive
- true
- exact text
- is indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2361
- qualifier mentions
- context exact
- is Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA).
- kind
- age
- polarity
- not_inferred
- span
- end
- 2401
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2395
- context exact
- 1.8 Rheumatoid Arthritis Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2381
- end exclusive
- true
- exact text
- Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2338
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 2433
- end exclusive
- true
- exact text
- 1.8 Rheumatoid Arthritis Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA).
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2313
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 24 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2716
- end exclusive
- true
- exact text
- l trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen. 1.8 Rheumatoid Arthritis Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA). 1.9 Polyarticular Juvenile Idiopathic Arthritis Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA). 1.10 Psoriasis Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2234
- current approval status
- not_reconciled
- duplicate text group
- dup-d75b7445c0e86d51a9aa
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-e7c6491d5d5278d05525
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 2517
- end exclusive
- true
- exact text
- is indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2505
- qualifier mentions
- context exact
- is Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA).
- kind
- age
- polarity
- not_inferred
- span
- end
- 2557
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2539
- context exact
- 1.9 Polyarticular Juvenile Idiopathic Arthritis Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2525
- end exclusive
- true
- exact text
- Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2482
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 2614
- end exclusive
- true
- exact text
- 1.9 Polyarticular Juvenile Idiopathic Arthritis Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA).
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2434
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 25 · positive indication candidate
- application numbers
- NDA011719
- brand names
- Methotrexate
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2716
- end exclusive
- true
- exact text
- id arthritis (RA). 1.9 Polyarticular Juvenile Idiopathic Arthritis Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA). 1.10 Psoriasis Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2415
- current approval status
- not_reconciled
- duplicate text group
- dup-2997051fb780aedee30f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- METHOTREXATE
- id
- ind-span-34b356adf92e3eec23c3
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- positive predicate support span
- end
- 2665
- end exclusive
- true
- exact text
- is indicated
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2653
- qualifier mentions
- context exact
- is Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2693
- end exclusive
- true
- exact text
- adults
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2687
- context exact
- 1.10 Psoriasis Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2673
- end exclusive
- true
- exact text
- Methotrexate Injection is indicated for the
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2630
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source defined aliases
- source span
- end
- 2716
- end exclusive
- true
- exact text
- 1.10 Psoriasis Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.
- label id
- 95b8b8da-da4e-4bba-9038-3cf65f3d5c1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 08798381a28776fac0ab65f17f4863be025cb975b34ac2a160084940c0f8b94b
- start
- 2615
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%2295b8b8da-da4e-4bba-9038-3cf65f3d5c1a%22
- spl effective date
- 2025-06-10
- spl set id
- 0d63ba29-b692-41b4-87e8-351265c8273f
- spl version
- 19
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Preserved source evidence · Not medical advice
Triangle